$18.94
Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
Moonlake Immunotherapeutics Insider Sold Shares Worth $322,261, According to a Recent SEC Filing
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
MoonLake Immunotherapeutics' CFO Sells 39K Shares
Overview
52-week range
$5.95
$63
23% of range
Avg surprise (last 3)
-3.3%
Avg reaction (last 2)
+7.4%
100% positive
Latest IV / EM
122%
EM ±27.9% · $19 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.98 | $-0.91 | -7.7% | -55.6% | +10.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.10 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.87 | $-0.73 | -19.2% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.63 | $-0.76 | +17.1% | — | +4.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.56 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.39 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.18 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.91 | -$0.87 | -4.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-70M | — | $-71M | $-61M | $-47M | — | $-43M | $-31M |
| Net income | $-70M | — | $-70M | $-55M | $-40M | — | $-35M | $-24M |
| EPS (diluted) | $-0.98 | — | $-1.10 | $-0.87 | $-0.63 | — | $-0.56 | $-0.39 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $298M | $335M | $351M | $307M | $272M | $180M | $376M | $343M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $397M | $422M | $411M | $455M | $506M | $474M | $512M | $537M |
| Total assets | $400M | $424M | $414M | $460M | $511M | $478M | $518M | $545M |
| Long-term debt | $99M | $74M | $74M | $73M | $73M | $0 | — | — |
| Total liabilities | $146M | $120M | $123M | $102M | $99M | $25M | $23M | $15M |
| Total equity | $254M | $304M | $289M | $354M | $408M | $447M | $488M | $521M |